LAS VEGAS--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announces that new data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 ...

Randomized trials neutral for pump device in complex elective cases, STEMI with reperfusio ...

Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat ...

Seismic Pharma, a newly formed biopharmaceutical company, today announced its launch and initial financing led by Panacea Capital. The company has been formed to advance a portfolio of clinically ...

Add Yahoo as a preferred source to see more of our stories on Google. Most people who've had a heart attack—or who fear having one—focus on surviving the cardiovascular event itself. But what happens ...

Centers with multidisciplinary teams created to rapidly respond to cardiogenic shock are more likely to use invasive hemodynamic monitoring and advanced mechanical circulatory support (MCS), but less ...

DANVERS, Mass.--(BUSINESS WIRE)--To mark the five year anniversary of the study by Stretch, et al., on cost and outcomes trends for short-term mechanical circulatory support, Abiomed announces a ...

In the STEMI Door-to-Unload trial, use of Impella missed the mark in patients with anterior MI without cardiogenic shock.

Women with heart failure–related cardiogenic shock have worse outcomes and more vascular complications than men, a new analysis of registry data shows. "These data identify the need for us to continue ...

Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart ...